Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Venture Financing 19
Alios BioPharma Raises US$41 Million In Series B Venture Financing 19
Partnerships 20
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 20
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 21
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 22
Janssen Pharma Enters into Research Partnership with Beacon Discovery 23
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 24
Genomic Health Enters into Research Agreement with Janssen Pharma 25
Cerveau Technologies Enters into Agreement with Janssen Pharma 26
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 27
PeptiDream Enters into Agreement with Janssen Pharma 28
Janssen Pharma Enters into Partnership with Premier 29
Renova Therapeutics Enters into Agreement with Janssen Pharma 30
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 31
Karolinska Institutet Partners with Johnson & Johnson Companies 32
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 33
Janssen Pharma Enters into Partnership with Bird Rock Bio 34
DiamiR Enters into Research Agreement with Janssen Pharma 35
Janssen Pharma Enters into Agreement with University of Pennsylvania 36
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 37
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 38
Janssen Pharma Enters into Agreement with University of California, San Diego 39
Cypralis Enters into Research Agreement with Janssen Pharma 40
BlinkBio Enters into Discovery Agreement with Janssen Pharma 41
NeurOp Enters into Research Agreement with Janssen Pharma 42
AC Immune Enters into Research Agreement with Janssen Pharma 43
Alector Enters Into Research Agreement With Janssen Pharma 44
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 45
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 46
Mellitech Enters into Agreement with Janssen Pharma 48
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 49
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 50
Licensing Agreements 51
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 51
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 52
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 53
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 54
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 55
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 56
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 57
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 58
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 59
AC Immune Enters into Licensing Agreement with Janssen Pharma 60
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 61
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 63
Janssen Pharma Enters into Licensing Agreement with BiocerOX 64
Orion Enters Into Licensing Agreement With Janssen Pharma 65
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 66
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 67
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 68
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 69
Shionogi Enters Into Licensing Agreement With Janssen Pharma 71
Depomed Enters Into Licensing Agreement With Janssen Pharma 72
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 73
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 74
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 75
Asset Transactions 77
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 77
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 78
Vivus Acquires Topiramate Related Patents from Janssen Pharma 80
Acquisition 81
Janssen Pharma Acquires XO1 81
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 82
Janssen Pharmaceuticals Inc – Key Competitors 84
Janssen Pharmaceuticals Inc – Key Employees 85
Janssen Pharmaceuticals Inc – Locations And Subsidiaries 86
Head Office 86
Other Locations & Subsidiaries 86
Recent Developments 87
Legal and Regulatory 87
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 87
Government and Public Interest 88
Feb 21, 2018: New Real-World Analysis Published in The Journal of Clinical Psychiatry Illuminates the Significant Economic Toll of Treatment-Resistant Depression on Individuals, Employers and Payers 88
Nov 30, 2017: New HIV Prevention Trials Hold Promise for New Prevention Options for Women 89
Sep 26, 2017: Janssen Announces HealtheVoices Impact Fund Recipients 90
Other Significant Developments 91
Oct 09, 2017: Johnson & Johnson investing $350M in EU biologics operation, adding 200 jobs 91
Appendix 92
Methodology 92
About GlobalData 92
Contact Us 92
Disclaimer 92
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Janssen Pharma Acquires CERC-501 from Cerecor 17
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 18
Alios BioPharma Raises US$41 Million In Series B Venture Financing 19
GenomeDx Biosciences Enters into Agreement with Janssen Pharma 20
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 21
Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 22
Janssen Pharma Enters into Research Partnership with Beacon Discovery 23
Beacon Discovery Enters into Co-Development Agreement with Janssen Pharma 24
Genomic Health Enters into Research Agreement with Janssen Pharma 25
Cerveau Technologies Enters into Agreement with Janssen Pharma 26
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 27
PeptiDream Enters into Agreement with Janssen Pharma 28
Janssen Pharma Enters into Partnership with Premier 29
Renova Therapeutics Enters into Agreement with Janssen Pharma 30
Janssen Pharma Enters into Agreement with Medicines for Malaria Venture 31
Karolinska Institutet Partners with Johnson & Johnson Companies 32
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 33
Janssen Pharma Enters into Partnership with Bird Rock Bio 34
DiamiR Enters into Research Agreement with Janssen Pharma 35
Janssen Pharma Enters into Agreement with University of Pennsylvania 36
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 37
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 38
Janssen Pharma Enters into Agreement with University of California, San Diego 39
Cypralis Enters into Research Agreement with Janssen Pharma 40
BlinkBio Enters into Discovery Agreement with Janssen Pharma 41
NeurOp Enters into Research Agreement with Janssen Pharma 42
AC Immune Enters into Research Agreement with Janssen Pharma 43
Alector Enters Into Research Agreement With Janssen Pharma 44
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 45
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 46
Mellitech Enters into Agreement with Janssen Pharma 48
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 49
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 50
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 51
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 52
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 53
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 54
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 55
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 56
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 57
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 58
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 59
AC Immune Enters into Licensing Agreement with Janssen Pharma 60
Minerva Amends Licensing Agreement with Janssen Pharma for MIN-202 61
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 63
Janssen Pharma Enters into Licensing Agreement with BiocerOX 64
Orion Enters Into Licensing Agreement With Janssen Pharma 65
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 66
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 67
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 68
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 69
Shionogi Enters Into Licensing Agreement With Janssen Pharma 71
Depomed Enters Into Licensing Agreement With Janssen Pharma 72
Janssen Pharma Enters into Licensing Agreement with Arcturus Therapeutics 73
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 74
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 75
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 77
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 78
Vivus Acquires Topiramate Related Patents from Janssen Pharma 80
Janssen Pharma Acquires XO1 81
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 82
Janssen Pharmaceuticals Inc, Key Competitors 84
Janssen Pharmaceuticals Inc, Key Employees 85
Janssen Pharmaceuticals Inc, Other Locations 86
Janssen Pharmaceuticals Inc, Subsidiaries 86
List of Figures
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Janssen Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Janssen Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11